Korian
Market Cap
€3.4b
Last Updated
2021/01/15 19:50 UTC
Data Sources
Company Financials +
Executive Summary
Korian provides integrated health and care services for the elderly in France, Germany, Belgium, Italy, Spain, and the Netherlands. More Details
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with moderate growth potential.
Similar Companies
Share Price & News
How has Korian's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KORI is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: KORI's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-1.8%
KORI
0.8%
FR Healthcare
-1.7%
FR Market
1 Year Return
-24.4%
KORI
-9.2%
FR Healthcare
-4.5%
FR Market
Return vs Industry: KORI underperformed the French Healthcare industry which returned -9% over the past year.
Return vs Market: KORI underperformed the French Market which returned -2.4% over the past year.
Shareholder returns
| KORI | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.8% | 0.8% | -1.7% |
| 30 Day | 7.2% | 3.6% | 1.1% |
| 90 Day | 18.6% | 15.4% | 12.9% |
| 1 Year | -18.2%-24.4% | -7.0%-9.2% | -2.7%-4.5% |
| 3 Year | 33.0%18.3% | 15.8%10.1% | 15.1%5.5% |
| 5 Year | 22.6%4.7% | 49.7%37.6% | 65.2%40.6% |
Long-Term Price Volatility Vs. Market
How volatile is Korian's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
If You Had Bought Korian's (EPA:KORI) Shares A Year Ago You Would Be Down 23%2 weeks ago | Simply Wall St
Is There An Opportunity With Korian's (EPA:KORI) 46% Undervaluation?1 month ago | Simply Wall St
What Does Korian's (EPA:KORI) Share Price Indicate?Valuation
Is Korian undervalued compared to its fair value and its price relative to the market?
43.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: KORI (€31.9) is trading below our estimate of fair value (€56.86)
Significantly Below Fair Value: KORI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: KORI is good value based on its PE Ratio (35.4x) compared to the FR Healthcare industry average (36.9x).
PE vs Market: KORI is poor value based on its PE Ratio (35.4x) compared to the French market (23.4x).
Price to Earnings Growth Ratio
PEG Ratio: KORI is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: KORI is good value based on its PB Ratio (1x) compared to the FR Healthcare industry average (2.4x).
Next Steps
Future Growth
How is Korian forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
54.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KORI's forecast earnings growth (54.1% per year) is above the savings rate (0.4%).
Earnings vs Market: KORI's earnings (54.1% per year) are forecast to grow faster than the French market (23.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: KORI's revenue (5.5% per year) is forecast to grow slower than the French market (7% per year).
High Growth Revenue: KORI's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KORI's Return on Equity is forecast to be low in 3 years time (5.6%).
Next Steps
Past Performance
How has Korian performed over the past 5 years?
7.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KORI has a large one-off loss of €31.0M impacting its June 30 2020 financial results.
Growing Profit Margin: KORI's current net profit margins (2%) are lower than last year (3.4%).
Past Earnings Growth Analysis
Earnings Trend: KORI's earnings have grown by 7.4% per year over the past 5 years.
Accelerating Growth: KORI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: KORI had negative earnings growth (-37.5%) over the past year, making it difficult to compare to the Healthcare industry average (-15.4%).
Return on Equity
High ROE: KORI's Return on Equity (2.8%) is considered low.
Next Steps
Financial Health
How is Korian's financial position?
Financial Position Analysis
Short Term Liabilities: KORI's short term assets (€1.3B) do not cover its short term liabilities (€1.9B).
Long Term Liabilities: KORI's short term assets (€1.3B) do not cover its long term liabilities (€7.3B).
Debt to Equity History and Analysis
Debt Level: KORI's debt to equity ratio (102.8%) is considered high.
Reducing Debt: KORI's debt to equity ratio has increased from 67% to 102.8% over the past 5 years.
Debt Coverage: KORI's debt is well covered by operating cash flow (26.2%).
Interest Coverage: KORI's interest payments on its debt are well covered by EBIT (3.2x coverage).
Balance Sheet
Next Steps
Dividend
What is Korian current dividend yield, its reliability and sustainability?
2.18%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KORI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KORI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KORI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KORI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: KORI is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KORI's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.3yrs
Average management tenure
CEO
Sophie Boissard (50 yo)
5yrs
Tenure
€957,765
Compensation
Ms. Sophie Boissard has been the Chief Executive Officer at Korian SA since January 26, 2016 and its Director since June 22, 2020. Ms. Boissard serves as an Executive in Railway Operator SNCF. She serves a...
CEO Compensation Analysis
Compensation vs Market: Sophie's total compensation ($USD1.16M) is below average for companies of similar size in the French market ($USD1.73M).
Compensation vs Earnings: Sophie's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5yrs | €957.77k | 0.017% € 561.6k | |
| Chief Financial Officer | 2.75yrs | no data | no data | |
| Chief Information Officer | no data | no data | no data | |
| Vice President of Investor Relations & Financing | no data | no data | no data | |
| General Counsel & Secretary of the Board | no data | no data | no data | |
| Group Chief Communication Officer | 3.58yrs | no data | no data | |
| Director of Group Strategy | no data | no data | no data | |
| Group Chief Human Resources & CSR Officer | 4.33yrs | no data | no data | |
| Chairman of the Medidep Management Board | 14.33yrs | no data | no data | |
| Deputy Chief Executive Officer | no data | €59.22k | no data | |
| Head of Ethical Development Department | no data | no data | no data | |
| Group Chief International Development Officer | no data | no data | no data |
4.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: KORI's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5yrs | €957.77k | 0.017% € 561.6k | |
| Chairwoman of Korian Italy | no data | no data | no data | |
| Independent Chairman of the Board | 0.25yr | €60.26k | 0.0016% € 53.2k | |
| Board Observer | 3.58yrs | €10.75k | 0.0014% € 48.8k | |
| Independent Director | 6.83yrs | €58.74k | 0.0066% € 221.3k | |
| Independent Director | 6.83yrs | €45.46k | 0.0011% € 37.7k | |
| Director | 0.58yr | no data | no data | |
| Director | 6.83yrs | no data | no data | |
| Independent Director | 1.58yrs | €40.41k | 0.00019% € 6.4k | |
| Independent Director | 3.58yrs | €51.60k | 0.000070% € 2.4k | |
| Director | 2.08yrs | €26.59k | no data | |
| Director | 1.33yrs | €12.04k | no data |
2.1yrs
Average Tenure
59yo
Average Age
Experienced Board: KORI's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27%.
Top Shareholders
Company Information
Korian's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Korian
- Ticker: KORI
- Exchange: ENXTPA
- Founded: 2001
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: €3.369b
- Shares outstanding: 105.02m
- Website: https://www.korian.com/fr
Number of Employees
Location
- Korian
- 21-25 rue Balzac
- Paris
- Ile-de-France
- 75008
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| KORI | ENXTPA (Euronext Paris) | Yes | Common Stock | FR | EUR | Nov 2006 |
| KO2 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2006 |
| 0OPS | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Nov 2006 |
| KORIP | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | EUR | Nov 2006 |
| KRMD.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Nov 2006 |
Biography
Korian provides integrated health and care services for the elderly in France, Germany, Belgium, Italy, Spain, and the Netherlands. The company operates long-term care nursing homes, specialized clinics, a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/15 19:50 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.